IMUX expects pivotal phase III vidofludimus calcium data by year-end
Vidofludimus calcium is advancing through pivotal phase III trials in relapsing MS. The program targets key data readouts by year-end and aims for an NDA submission next year.
Vidofludimus calcium is moving through pivotal phase III trials in relapsing multiple sclerosis, with a dual mechanism aimed at inflammation and neurodegeneration. The program remains on track for key data readouts by year-end and is targeting NDA submission next year. The company says the treatment is aimed at addressing major unmet needs in a large, dy…